STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

Kiniksa Pharmaceuticals (Nasdaq: KNSA) has announced it will host a conference call and live webcast on Tuesday, February 25, 2025 at 8:30 a.m. Eastern Time to report its fourth quarter and full year 2024 financial results and recent portfolio execution. The event will be accessible through the Investors & Media section of the company's website. Interested participants can register for telephone access, and a replay will be available on the website within 48 hours after the event.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

LONDON, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, February 25, 2025 at 8:30 a.m. Eastern Time to report its fourth quarter and full year 2024 financial results and recent portfolio execution.

A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event.

About Kiniksa
Kiniksa is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating diseases by discovering, acquiring, developing, and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Kiniksa’s portfolio assets are based on strong biologic rationale or validated mechanisms and offer the potential for differentiation. For more information, please visit www.kiniksa.com.

Every Second Counts! ®

Kiniksa Investor Contact
Jonathan Kirshenbaum
(781) 829-3949
jkirshenbaum@kiniksa.com

Kiniksa Media Contact
Tyler Gagnon
(781) 431-9100
tgagnon@kiniksa.com


FAQ

When will Kiniksa Pharmaceuticals (KNSA) report Q4 and full-year 2024 earnings?

Kiniksa Pharmaceuticals will report its Q4 and full-year 2024 financial results on Tuesday, February 25, 2025, at 8:30 a.m. Eastern Time.

How can investors access KNSA's Q4 2024 earnings call?

Investors can access the earnings call through a live webcast on Kiniksa's website (Investors & Media section) or by registering for telephone access.

Will KNSA's Q4 2024 earnings call be available for replay?

Yes, a replay of the earnings call will be available on Kiniksa's website within approximately 48 hours after the event.

What topics will be covered in KNSA's Q4 2024 earnings call?

The call will cover Kiniksa's fourth quarter and full year 2024 financial results and recent portfolio execution.
Kiniksa Pharmaceuticals International, plc

NASDAQ:KNSA

KNSA Rankings

KNSA Latest News

KNSA Latest SEC Filings

KNSA Stock Data

3.22B
43.64M
3.74%
92.97%
3.65%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United Kingdom
LONDON